Callan JMB agreed with Attune Biotech to oversee manufacturing and quality control for Attune’s investigational new drug clinical trials of lodonal for Long COVID. Under the agreement, Callan JMB will provide independent oversight of manufacturing, quality assurance and control, and deployment operations. Services include contract manufacturing organization qualification and validation, batch record review, and supply chain verification. The collaboration covers IND 181314 for JKB-122 (lodonal), for which Attune plans a randomized, double-blind, placebo-controlled, multi-center Phase 2b/3 trial in adults with PASC.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Callan JMB Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110845PRIMZONEFULLFEED9669766) on March 11, 2026, and is solely responsible for the information contained therein.